logo-loader
viewInnovaDerma PLC

Capital Network's analyst Ed Stacey on Innovaderma's strong growth drivers being ready to kick in

Analyst Ed Stacey talks investors through InnovaDerma (LON:IDP) reported results on 21 February for the first half of the full year (FY) to June 2019. Results were in line with January's trading statement, with first half (H1) revenues down 7.5% driven by disruptions to the direct-to-consumer (DTC) sales channel. The company has indicated that a number of elements are in place to drive a strong acceleration in H2 - DTC Issues resolved, major new high-street retail channels, ongoing growth in the Roots haircare range.
The shares have de-rated materially in valuation terms and now trade on a 2019e price/earnings (P/E) multiple of 9.9x and enterprise value (EV)/sales of 0.9x. These multiples are pricing-in a low probability of strong revenue growth resuming says Ed. The H1 release discloses +37% revenue growth in the first six weeks of H2, and he notes that this is without yet realising the benefit of new retail channels to begin in March. Ed examinse the valuation in this report, and concludes that there is substantial upside potential.

Quick facts: InnovaDerma PLC

Price: 60.5 GBX

LSE:IDP
Market: LSE
Market Cap: £8.77 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnovaDerma PLC named herein, including the promotion by the Company of InnovaDerma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

InnovaDerma PLC's growth trajectory 'very much back on track'

Capital Network's Ed Stacey discusses InnovaDerma (LON:IDP) following the release of their results for the year to the end of June 2018. These were in line with market expectations, with 21% like-for-like revenue growth. InnovaDerma specialises in the development, manufacture and...

on 22/9/18

2 min read